Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables - A Framework and Implementation Roadmap
Therapeutic Innovation & Regulatory Science · 2025
DOI: 10.1007/s43441-025-00844-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Linda Smeding und 6 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Avenue Fleming 20, Wavre, 1300, Belgium. linda.x.smeding@gsk.com. Hauptthemen laut MEDLINE: Pharmacovigilance, Patient Participation. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Various initiatives and guidelines exist to support patient engagement (PE) throughout the lifecycle of a medicinal product. While the recent European Medicines Agency guideline on good pharmacovigilance practices (Module XVI; Revision 3) reinforces the importance of involving patients to create effective risk minimization strategies, frameworks supporting the systematic adoption of PE by Marketing Authorization Holders (MAHs) across pharmacovigilance, including the risk management system, are lacking. Furthermore, little is presented on the impact of patient review of additional risk minimization measures materials. We present a tested Pharmacovigilance Patient Centricity Framework describing key focus areas that can create the necessary infrastructure for systematic PE in effective risk minimization materials. Implementation of this framework highlighted the importance of collaboration to drive PE across the company at both local and global level, and externally, as relationships are established with patient organizations and best practices are shared with other MAHs. Therefore, this framework can be considered by other companies as a basis for developing a patient-centric approach to integrate the patient’s voice into pharmacovigilance deliverables.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GSK, Avenue Fleming 20, Wavre, 1300, Belgium. linda.x.smeding@gsk.com.
- GSK, London, UK.
- GSK, Philadelphia, USA.
- GSK, Baar, Switzerland.
- GSK, Munich, Germany.
- GSK, Verona, Italy.
Förderung
- GSK
Zitieren
APA
Smeding, L., Massouh, R., Moyo, F., Metcalf, M., Altimari, S., Edle von Dall'Armi, E., & Formenti, E. (2025). Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables - A Framework and Implementation Roadmap. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00844-5
Vancouver
Smeding L, Massouh R, Moyo F, Metcalf M, Altimari S, Edle von Dall'Armi E, et al. Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables - A Framework and Implementation Roadmap. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00844-5
BibTeX
@article{Smeding2025,
author = {Smeding, Linda and Massouh, Robert and Moyo, Farai and Metcalf, Marilyn and Altimari, Shannon and Edle von Dall'Armi, Ekaterina and Formenti, Elisa},
title = {Incorporating Patient Needs and Perspectives in Additional Risk Minimization Measures and Other Pharmacovigilance Deliverables - A Framework and Implementation Roadmap},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2025},
doi = {10.1007/s43441-025-00844-5}
}
EUVIMED